Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM | BSE: 500420 | ISIN: INE685A01028 | Industry: Pharmaceuticals
| Expensive Performer
3545.8000 -21.30 (-0.60%)
NSE Oct 03, 2025 10:16 AM
Volume: 86,168
 

3545.80
-0.60%
Reliance Securities
ff India Biz (40% of Sales): TRP's domestic business grew by 16.5% YoY, which adjusted for Unichem acquisition and GST roll-out related changes, grew by 13% YoY. During 3QFY18, TRP booked Unichem sales from 14th to 31st Dec-17, as part of its domestic business. As per management, sales growth of the acquired business is still slow due to integration with TRP. Further, despite re-stocking post GST roll-out, inventory is yet to match pre-GST level (14 days vs. 21 days). Led by Unichem acquisition, product overlap stood at ~70% while doctor overlap at ~90%. TRP expects any cost synergies driven by the overlaps to be limited due to higher rural penetration of Unichem's products (70% vs. 30% of TRP). The Management...
Torrent Pharmaceuticals Ltd.'s price crossed below 30Day SMA today
More from Torrent Pharmaceuticals Ltd.
Recommended